Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency (Kamada API)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00460096 |
Recruitment Status
:
Completed
First Posted
: April 13, 2007
Last Update Posted
: October 17, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Alpha 1-Antitrypsin Deficiency | Drug: Kamada-API | Phase 2 Phase 3 |
Alpha-1 Antitrypsin Deficiency, also called Alpha-1-Proteinase Inhibitor (API) deficiency, is a genetic disorder characterized by the production of an abnormal amount of AAT protein and reduced circulating levels of this protein. Subjects with AAT deficiency are at increased risk for developing chronic obstructive pulmonary disease (COPD). It is believed that this is the result of the chronic activity of elastase released by cells continually present in the lungs in low numbers.
This study is a randomized, double-blind comparison of Kamada API, an Alpha-1-Proteinase Inhibitor with a currently marketed API product.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 50 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Double |
Primary Purpose: | Treatment |
Official Title: | Randomized Double-Blind Comparison of an Alpha-1 Proteinase Inhibitor (Kamada API) With a Currently Marketed API Product in Individuals With Alpha-1 Antitrypsin Deficiency |
Study Start Date : | March 2007 |
Actual Study Completion Date : | September 2007 |

- Efficacy
- Safety

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Signed informed consent.
- "At-risk" alleles associated with serum AAT < 11 μM including null alleles and deficiency alleles. This must be documented in the subject's history or laboratory tests performed at screening.
- At least 18 years of age.
-
Evidence of lung disease related to AAT deficiency, identified by at least one of the following:
- FEV1<80% predicted (post BD); or
- Loss of lung function over a one year period of greater than 35ml in FEV1; or
- HRCT evidence of pulmonary emphysema
- For actively treated subjects, agreement to not receive any exogenous API product (i.e. washout) for five weeks prior to first study infusion.
- Use of an effective means of contraception during the 24 weeks of study drug administration (this is applicable to both sexes).
- Subjects on the BAL, bronchial brushing/biopsy group must be on inhaled corticosteroids at a stable dose two weeks prior the first Bronchoscopy and throughout the dosing period up the final bronchoscopy.
Exclusion Criteria:
- Laboratory evidence of severe IgA deficiency (from medical history or by IgA testing at screening of at least 20% of lower range).
- Current smoker or a history of smoking within the past 3 months.
- History of allergy to plasma proteins.
- Participation in another experimental drug or device trial within the past 30 days.
- Evidence of uncontrolled hypertension (systolic ≥180 mm Hg, and/or diastolic ≥ 110 mm Hg on 3 consecutive occasions in the supine position)
- Pulse ≥ 120/min (prior to the 1st infusion).
- Abnormal screening or baseline laboratory measurements that in the opinion of the Investigator would affect subject safety.
- Pregnancy or lactation.
- Current life-threatening malignancy.
- Previous organ transplant recipient.
- History of infection with HCV, HBV and/or HIV 1 or 2, or (at baseline) infection indicated by laboratory measurements obtained at screening.
- Acute respiratory tract infection or COPD exacerbation which required antibiotic and/or systemic steroid treatment within the past 6 weeks. Patient can be re-evaluated for enrollment 6 weeks after an exacerbation.
- Any other condition which in the judgment of the investigator may interfere with the conduct of the study.
- If an adequate home health care agency cannot be established by Centric Health Resources due to a potential subject's geographical location.
Exclusion criteria for subjects entering into the BAL and bronchial biopsy/brushing:
- FEV1 < 45% predicted (post-BD).
- Inability to undergo bronchoscopy.
- Allergy to lidocaine.
- Exacerbation of COPD in the previous 6 weeks.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00460096
United States, Colorado | |
National Jewish Medical and Research Center | |
Denver, Colorado, United States, 80206 | |
United States, Florida | |
University of Florida School of Medicine | |
Gainesville, Florida, United States, 32610 | |
United States, Texas | |
The University of Texas Health Center at Tyler | |
Tyler, Texas, United States, 75708-3154 |
Principal Investigator: | Robert A Sandhaus, M.D. | National Jewish Health |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: | NCT00460096 History of Changes |
Other Study ID Numbers: |
Kamada API-002 |
First Posted: | April 13, 2007 Key Record Dates |
Last Update Posted: | October 17, 2007 |
Last Verified: | October 2007 |
Keywords provided by Kamada, Ltd.:
Pulmonary Emphysema |
Additional relevant MeSH terms:
Alpha 1-Antitrypsin Deficiency Alpha 1-Antitrypsin Protein C Inhibitor Liver Diseases Digestive System Diseases Lung Diseases Respiratory Tract Diseases Genetic Diseases, Inborn |
Subcutaneous Emphysema Emphysema Pathologic Processes Protease Inhibitors Trypsin Inhibitors Serine Proteinase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |